REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN) from its SEC filings: 2025 revenue $738.3 million (+16% vs the year before), net margin 7%, free cash flow $93.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $738.3 million |
| Revenue growth | +16% |
| Net income | $48.9 million |
| Net margin | 6.6% |
| Free cash flow | $93.9 million |
| Diluted EPS | $0.86 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +12% |
| Cash | $606.8 million |
| Long-term debt | $551.0 million |
| Share count, 1 year | +0% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.